Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:150032.
doi: 10.1530/EDM-15-0032. Epub 2015 Jun 1.

Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease

Affiliations

Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease

Avital Nahmias et al. Endocrinol Diabetes Metab Case Rep. 2015.

Abstract

Approximately 35% of the pancreatic neuroendocrine tumors (pNETs) are functional, the most common of which is an insulinoma. Rarely can initially nonfunctioning tumor undergo biological transformation to a hormone-secreting tumor with subsequent changes in the clinical picture. We present here three unique patients with long-standing pNETs who developed life-threatening hyperinsulinemic hypoglycemia along with tumor progression. In two of the patients, everolimus (Afinitor) was administered in an attempt to control both tumor growth and hypoglycemia. In two cases everolimus therapy resulted in the abolishment of hypoglycemia and induced significant tumor regression; however these beneficial responses were transient. These cases highlight the exceptional ability of pNETs to change biological behavior in parallel with disease progression. Our experience concurs with recently published studies demonstrating the utility of everolimus for the control of both hypoglycemia and tumor progression.

Learning points: Nonfunctional pNET can gain new features such as insulin secretion with related morbidity.Gain of function in a previously nonfunctional pNET signifies tumor progression and is usually associated with poor prognosis.Everolimus proved to be a viable treatment for hypoglycemia in insulinoma patients and was also proven highly effective in the patients presented here.As disease progresses, the effect of everolimus on hypoglycemia wanes. We report for the first time the development of hypoglycemia during everolimus treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
68Gallium-DOTATATE PET–CT of the first patient showing high uptake by the pancreatic and hepatic masses.
Figure 2
Figure 2
68Gallium-DOTANOC PET–CT of the second patient indicating diffuse involvement of liver, reflecting a salt-and-pepper appearance.
Figure 3
Figure 3
68Gallium-DOTATATE PET–CT of the third patient showing bilobar hepatic metastatic spread and a retroperitoneal conglomerate of lymph nodes.

References

    1. Vinik AI. 2014. Advances in diagnosis and treatment of pancreatic neuroendocrine tumors. Endocrine Practice 20 1222–1230. 10.4158/EP14373.RA - DOI - PubMed
    1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063–3072. 10.1200/JCO.2007.15.4377 - DOI - PubMed
    1. Vashi PG, Gupta D & Dahlk S. 2011. A unique case of a nonfunctional metastatic pancreatic neuroendocrine tumor transforming into an insulin-secreting tumor with an unusual clinical course. Pancreas 40 781–784. 10.1097/MPA.0b013e318212c42d - DOI - PubMed
    1. Ohn JH, Kim YG, Lee SH & Jung HS. 2013. Transformation of nonofuctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib. Endocrinology and Metabolism 28 149–152. 10.3803/EnM.2013.28.2.149 - DOI - PMC - PubMed
    1. Meric-Bernstam F & Gonzalez-Angulo AM. 2009. Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology 27 2278–2287. 10.1200/JCO.2008.20.0766 - DOI - PMC - PubMed

LinkOut - more resources